Dover Advisors LLC Has $356,000 Position in Pfizer Inc. $PFE

by · The Cerbat Gem

Dover Advisors LLC cut its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 35.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 14,690 shares of the biopharmaceutical company’s stock after selling 7,943 shares during the quarter. Dover Advisors LLC’s holdings in Pfizer were worth $356,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Gould Capital LLC raised its stake in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares during the period. GKV Capital Management Co. Inc. bought a new position in Pfizer during the 1st quarter worth $27,000. North Capital Inc. acquired a new stake in shares of Pfizer during the 1st quarter worth $28,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the 1st quarter worth $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the 4th quarter worth $30,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on PFE shares. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. HSBC reduced their price objective on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Berenberg Bank reduced their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Jefferies Financial Group raised their price objective on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. Finally, Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.12.

Check Out Our Latest Stock Analysis on PFE

Pfizer Price Performance

Shares of PFE opened at $23.91 on Monday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $135.94 billion, a price-to-earnings ratio of 12.72, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The business has a 50-day moving average of $24.79 and a 200-day moving average of $24.27.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the company earned $0.60 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).